NEW YORK ( TheStreet -- Many Chinese IPOs have seen success in the aftermarket, and Mecox Lane Limited ( MCOX), which debuted on the Nasdaq exchange Tuesday was no exception. The Shanghai-based online apparel retailer priced an offering of 11.7 million shares at $11 each, and saw the stock rocket almost 60% to close at $17.26. Mecox's surge follows the market's warm reception of Country Style Cooking Restaurant ( CCSC), the Chinese fast food chain that began trading at $24 in September and currently changes hands at roughly $34 a share for a gain for 38%. Another example is China New Borun ( BORN), which sells alcoholic beverages. The company went public in June at $7 per share and the stock now trades at around $16, a whopping 140% gain. Then there's the rare earth mineral company Molycorp ( MCP), that has soared to $35 from its original price of $12. But with every IPO success story, Chinese or no, there seems to an equally dismal offering. One such name is NuPathe ( PATH), a pharmaceutical company that launched in August at $10 a share and has sunk to $6. Trius Therapeutics ( TSRX) hasn't fared much better as it dropped from an initial $5 a share to $4 for a 20% decline. But it's not just small drug companies that have fallen flat. SMART Technologies ( SMT) went public at $17 and has tumbled to $13.50, also a 20% loss. So investors need to do a little homework if they want to informed decisions about these IPOs. Here are this week's offerings and their chances of success.